Based on an acceptable safety profile and promising clinical activity, the combination has now been advanced to a Phase IIa study at the BIDMC and DFCI to assess therapeutic efficacy.
Based on an acceptable safety profile and promising clinical activity, the combination has now been advanced to a Phase IIa study at the BIDMC and DFCI to assess therapeutic efficacy.
|
Company |
|